Free Trial
NASDAQ:ENTA

Enanta Pharmaceuticals (ENTA) Stock Price, News & Analysis

Enanta Pharmaceuticals logo
$5.30 -0.02 (-0.38%)
Closing price 04/2/2025 04:00 PM Eastern
Extended Trading
$6.62 +1.33 (+25.00%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Enanta Pharmaceuticals Stock (NASDAQ:ENTA)

Key Stats

Today's Range
$5.21
$5.50
50-Day Range
$4.90
$8.49
52-Week Range
$4.71
$17.60
Volume
171,984 shs
Average Volume
277,514 shs
Market Capitalization
$113.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.25
Consensus Rating
Moderate Buy

Company Overview

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Remove Ads

Enanta Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
72nd Percentile Overall Score

ENTA MarketRank™: 

Enanta Pharmaceuticals scored higher than 72% of companies evaluated by MarketBeat, and ranked 276th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Enanta Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Enanta Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about Enanta Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Enanta Pharmaceuticals are expected to decrease in the coming year, from ($4.65) to ($4.98) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Enanta Pharmaceuticals is -1.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Enanta Pharmaceuticals is -1.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Enanta Pharmaceuticals has a P/B Ratio of 1.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Enanta Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    13.27% of the float of Enanta Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Enanta Pharmaceuticals has a short interest ratio ("days to cover") of 5.2.
  • Change versus previous month

    Short interest in Enanta Pharmaceuticals has recently increased by 1.15%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Enanta Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Enanta Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.27% of the float of Enanta Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Enanta Pharmaceuticals has a short interest ratio ("days to cover") of 5.2.
  • Change versus previous month

    Short interest in Enanta Pharmaceuticals has recently increased by 1.15%, indicating that investor sentiment is decreasing.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Enanta Pharmaceuticals this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Enanta Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $256,050.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    13.89% of the stock of Enanta Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    94.99% of the stock of Enanta Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Enanta Pharmaceuticals' insider trading history.
Receive ENTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ENTA Stock News Headlines

BITCOIN
Did you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this...
See More Headlines

ENTA Stock Analysis - Frequently Asked Questions

Enanta Pharmaceuticals' stock was trading at $5.75 at the start of the year. Since then, ENTA shares have decreased by 7.8% and is now trading at $5.30.
View the best growth stocks for 2025 here
.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced its earnings results on Monday, February, 10th. The biotechnology company reported ($1.05) earnings per share for the quarter, topping the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative net margin of 157.57% and a negative trailing twelve-month return on equity of 75.53%.

Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Enanta Pharmaceuticals investors own include Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Netflix (NFLX), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD) and Alphabet (GOOG).

Company Calendar

Last Earnings
2/10/2025
Today
4/03/2025
Next Earnings (Estimated)
5/05/2025
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ENTA
Employees
160
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$17.25
High Stock Price Target
$21.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+225.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-116,040,000.00
Net Margins
-157.57%
Pretax Margin
-159.88%

Debt

Sales & Book Value

Annual Sales
$66.59 million
Price / Cash Flow
N/A
Book Value
$5.24 per share
Price / Book
1.01

Miscellaneous

Free Float
18,370,000
Market Cap
$113.06 million
Optionable
Optionable
Beta
0.47

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:ENTA) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners